Catalyst Bio

CBIO NASDAQ
7.32
-0.17
-2.27%
After Hours: 7.32 0 0.00% 16:29 06/20 EDT
Open
7.60
Prev Close
7.49
High
7.66
Low
7.21
Volume
48.17K
Avg Vol (3M)
156.27K
52 Week High
14.37
52 Week Low
6.20
% Turnover
0.40%
Market Cap
87.69M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Catalyst Bio CBIO stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
MORE >

Recently

Name
Price
%Change